Skip to main content
Download PDF

Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues

Retrovirology volume 8, Article number: 42 (2011) Cite this article

Abstract

Background

CD4-binding site (CD4bs) alterations in gp120 contribute to HIV-1 envelope (Env) mediated fusogenicity and the ability of gp120 to utilize low levels of cell-surface CD4. In a recent study, we constructed three-dimensional models of gp120 to illustrate CD4bs conformations associated with enhanced fusogenicity and enhanced CD4-usage of a modestly-sized panel of blood-derived HIV-1 Envs (n = 16). These conformations were characterized by a wider aperture of the CD4bs cavity, as constrained by the inner-most atoms at the gp120 V1V2 stem and the V5 loop. Here, we sought to provide further validation of the utility of these models for understanding mechanisms that influence Env function, by characterizing the structure-function relationships of a larger panel of Envs derived from brain and other tissues (n = 81).

Findings

Three-dimensional models of gp120 were generated by our recently validated homology modelling protocol. Analysis of predicted CD4bs structures showed correlations between the aperture width of the CD4bs cavity and ability of the Envs to mediate cell-cell fusion, scavenge low-levels of cell-surface CD4, bind directly to soluble CD4, and bind to the Env mAb IgG1b12 whose epitope overlaps the gp120 CD4bs. These structural alterations in the CD4bs cavity were associated with repositioning of the V5 loop.

Conclusions

Using a large, independent panel of Envs, we can confirm the utility of three-dimensional gp120 structural models for illustrating CD4bs alterations that can affect Env function. Furthermore, we now provide new evidence that these CD4bs alterations augment the ability of gp120 to interact with CD4 by increasing the exposure of the CD4bs.

Findings

The human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins (Env) mediate virus entry into cells and exist as trimers, comprising the surface gp120 glycoproteins noncovalently linked to transmembrane gp41 glycoproteins that embed the complex into the viral membrane [1–3]. HIV-1 entry is initiated by gp120 binding to cellular CD4, which facilitates the initial attachment of virus to the target cell [4]. The binding of gp120 to CD4 results in dramatic conformational changes in gp120 that expose the binding site for a secondary coreceptor, which is either of the chemokine receptors CCR5 or CXCR4 (reviewed in [5–7]).

Crystallographic and biochemical studies of gp120 have provided valuable insights into mechanisms involved in CD4 binding and CD4-induced conformational changes [3, 8–12]. The unliganded gp120 core of simian immunodeficiency virus (SIV) consists of a highly conserved inner domain which faces the trimer axis and a heavily glycosylated, globular outer domain which is mostly exposed on the surface of the trimer [8]. However, thermodynamic and structural analysis of the gp120-CD4 interaction demonstrated little evidence of a structured CD4 binding pocket on the unliganded gp120, and that CD4bs elements which influence gp120-CD4 affinity are formed from conformational alterations that occur after gp120 has encountered CD4 [2, 10]. CD4 interacts with gp120 via surface-exposed residues within three separate regions distributed over six segments of gp120. These regions include the α-helices of the inner domain, the CD4 binding loop of outer domain, and the β20-β21 ribbon which becomes part of the gp120 bridging sheet, which is a structural element of gp120 formed after CD4 binding that is involved in coreceptor binding [3, 11].

Changes in CD4 binding to gp120 contribute to different pathophysiological phenotypes of HIV-1, including the fusogenic properties of the Env [13, 14]. Env mediates most of the acute cytopathic effects of HIV-1 infection in cultured cells [15], and membrane fusion appears to be an important factor contributing to HIV-1 cytopathicity in vitro [16, 17]. In addition, enhancement of pathogenicity of chimeric simian-HIV (SHIV) strains in macaques frequently results from increased Env-mediated fusogenicity [18–22]. Moreover, the cytopathic effects of Env-mediated HIV-1 fusogenicity are evident in humans. For example, the presence of multinucleated giant cells in brain, formed by Env-mediated fusion between infected and uninfected macrophage lineage cells, is characteristic of HIV-1 encephalitis and a neuropathological hallmark of HIV-associated dementia [23].

To better understand the molecular mechanisms contributing to alterations in CD4 binding by primary gp120 proteins and the subsequent influence on Env function, we recently developed and validated a protocol to produce and utilize three-dimensional structural models of gp120 to deduce CD4bs alterations that influence CD4 binding and Env-mediated fusogenicity [13]. Using a modestly-sized panel of blood derived Envs (n = 16), we showed that a wider aperture of the predicted CD4bs cavity, as constrained by the inner-most atoms at the gp120 V1V2 stem and the V5 loop, contributed to increased fusogenicity and ability of gp120 to bind CD4. In the present study, we sought to provide further validation of the utility of these molecular models for understanding mechanisms that influence Env function, by characterizing, for the first time, the structure-function relationships of a larger panel of Envs derived from brain and other tissues (n = 81).

Production and characterization of a panel of primary Env clones

Primary HIV-1 viruses isolated from autopsy brain and/or cerebrospinal fluid, spinal cord, lymph node, spleen or PBMC from subjects CB1, CB3, MACS1, MACS2, MACS3, UK1 and UK7 have been described in detail previously [14, 24–27]. The clinical characteristics of the subjects and coreceptor usage profiles of the primary viruses are summarized in Table 1. A 2.1 kb fragment spanning the KpnI to BamHI restriction sites in HIV-1 env (corresponding to nucleotides 6348 to 8478 in HXB2) was amplified from viral cDNA by PCR and cloned into the pSVIII-HXB2 Env expression vector [28], as described previously [29–33]. Between 4 and 6 functional Envs from each virus were identified by entry assays in JC53 cells with Env-pseudotyped GFP reporter viruses, as described previously [30, 33–35] (Table 1). The coreceptor specificity of the cloned Envs was determined by entry assays in Cf2th-CD4/CCR5 and Cf2th-CD4/CXCR4 cells [35, 36] with Env-pseudotyped luciferase reporter viruses, as described previously [29, 35], which recapitulated the coreceptor usage of the primary viruses (Table 1). The Envs were sequenced in their entirety and subjected to multiple sequence alignments (data not shown) and phylogenetic analysis (Figure 1), which together showed that the Envs were independent and compartmentalized according to their tissue of origin. Thus, we established and characterized a new panel of Envs (n = 81) derived from autopsy brain and other tissues of 7 subjects who died from AIDS.

Table 1 Study subjects, HIV-1 isolates, and summary of Env phenotypes
Full size table
Figure 1
figure 1

Phylogenetic analysis of env nucleotide sequences. The phylogenetic tree was constructed from an env nucleotide multiple sequence alignment using a maximum likelihood algorithm, as described previously [39]. The nucleotide sequences of HIV-1 AD8, 89.6, JRCSF, YU2, NL4-3 and HXB2 env genes were included for comparison. Numbers associated with each branch are bootstrap values obtained from 1000 replicates. Only values above 700 for the major branches are shown. Branch lengths are proportional to the amount of sequence divergence.

Full size image

Production of three-dimensional gp120 models and characterization of the CD4bs cavity

We next produced three-dimensional structural models of each of the 81 Envs using a protocol that we described recently [13, 32]. Briefly, homology models of CD4-bound gp120 sequences were prepared using the Build Model protocol of the Discovery Studio suite, version 1.6 (Accelrys, San Diego, CA, USA). This approach used the Modeller algorithm to generate an atomic model of the target protein from a template molecule and a sequence alignment. The template-based models were optimized by iterative cycles of conjugate-gradient minimisation against a probability density function that included spatial restraints derived from the template and residue specific properties [37]. The crystal structure of JRFL gp120 containing the V3 variable loop and bound to CD4 and the X5 Fab antibody fragment was used as the template for CD4-bound models [9] (Protein Data Bank ID: 2B4C). The X5 antibody fragment was deleted from the CD4-bound template prior to modeling. The coordinates for gp120 and CD4 were extracted from the 2B4C crystal structure. Sequence alignments were generated between JRFL gp120 and the primary gp120 Env clones. The sequence for CD4 was included as a second polypeptide chain such that the models of gp120 were constructed as complexes with CD4. The V1V2 variable loops were replaced with a GAG linker sequence and the N- and C- termini overhangs were cut using the modeling software.

Similarities in three-dimensional structure were measured by the root mean square deviation (RMSD) of the distances between main-chain atoms (N, Cα, C and O atoms) from crystal and model structures after rigid body superposition, where an RMSD of < 1Å signifies a high level of three-dimensional structural similarity between overlayed proteins. The overall quality of the geometry of gp120 models generated was verified using PROCHECK [38].

The three-dimensional structural similarity between the 2B4C JRFL crystal structure and the 81 predicted structures of the primary gp120 proteins was < 1.0 Ã… for all the primary gp120 models (data not shown), indicating a high overall degree of structural similarity. Identical RMSD values for each gp120 model were obtained upon repeated, independent modeling operations (data not shown). The aperture width of the CD4bs cavity was deduced from each of the three-dimensional gp120 structural models by measuring the distance between the inner most atoms present at the stem of the V1V2 loops and the V5 loop, which constrain the CD4 binding pocket of gp120 [9]. Figure 2 shows the derivation of the CD4bs aperture width for the Macs2ln5 gp120 model as an example. Analysis of structural models generated for all the 81 Envs showed that the aperture width of the predicted CD4bs cavity ranges from 30 to 36 Ã… in this panel of Envs.

Figure 2
figure 2

Predicted alterations in the CD4bs cavity from three-dimensional gp120 models. The gp120 model of Macs2ln5 Env is shown in molecular surface representation, and the CD4 molecule is shown in blue Cα wire, with Phe43 of CD4 highlighted in yellow stick representation to show the "Phe43 cavity" of gp120. gp120 residues in the CD4 binding pocket located within 4 Å of the CD4 molecule are shown in ball and stick representation and their molecular surface is highlighted in blue. The width of the CD4bs aperture, as constrained by the inner-most atoms at the gp120 V1V2 stem and the V5 loop, was deduced as described previously [13].

Full size image

An increased aperture width of the gp120 CD4bs cavity is associated with increased fusogenicity, increased CD4-usage, and increased IgG1b12 Env mAb binding

To determine whether alterations in the width of the gp120 CD4bs aperture may influence Env function, we first performed quantitative cell-cell fusion assays with 293T effector cells expressing equivalent levels of Env on the cell surface, and target cells expressing coreceptor and either relatively high or relatively low levels of CD4 as described previously [13]. In these assays, we observed positive correlations between the width of the gp120 CD4bs cavity and the overall level of cell-cell fusion (Figure 3A), and also with the ability of Env to utilize low levels of CD4 to mediate cell-cell fusion (Figure 3B). Next, to better understand the influence of changes in the gp120 CD4bs aperture on CD4 binding and CD4bs exposure, we measured the ability of Env to bind sCD4 and the Env mAb IgG1b12, whose epitope overlaps the gp120 CD4bs, using a subset of Envs (n = 12, Macs1br2-8 and Macs1sp3-15; see Figure 1), as described previously [13, 35]. In these assays, we observed a near significant association between the width of the CD4bs cavity and ability of Env expressed on 293T cells to bind sCD4 (Figure 3C), and a significant correlation between this parameter and the ability of Env to bind IgG1b12 (Figure 3D). Together, these studies, using a large and newly-described panel of primary Envs, demonstrate the utility of three-dimensional modeling of the gp120 CD4bs cavity for better understanding the structural basis of Env-CD4 interactions, confirming the results of our recent study of a different and much smaller panel of Envs [13]. Furthermore, our results provide new evidence suggesting that these predicted CD4bs conformational alterations augment the ability of gp120 to interact with CD4 by increasing the exposure of the CD4bs.

Figure 3
figure 3

The effect of gp120 CD4bs cavity alterations on fusogenicity, CD4-dependence, sCD4 binding and CD4bs exposure. The CD4bs aperture widths for each gp120 model were plotted against the ability of Env to mediate cell-cell fusion (A), the ability of Env to utilize low levels of CD4 for cell-cell fusion (B), and the ability of Env to bind sCD4 (C) or the Env mAb IgG1b12 (D), using Prism version 5.0c (GraphPad Software). The methods for these functional and biochemical assays have been described in detail previously, including the extensive use of controls to ensure equivalent expression of Env on the cell surface, protocols for generating (and measuring CD4 expression on) CD4low and CD4high cells, and the empirical determination of sCD4 and IgG1b12 concentrations used that we showed were within the linear range of Env binding [13, 32, 35]. The Spearman correlation coefficient (r) and P values are shown. P values < 0.05 were considered statistically significant. The data shown are representative of 3 independent experiments.

Full size image

Repositioning of the V5 loop is associated with conformational alterations in the gp120 CD4bs

To elucidate the gp120 determinants which may contribute to structural alterations in the CD4bs and which subsequently influence CD4 interactions and fusogenicity, we next compared the structural similarity between CB3sc2 and Macs1br3 gp120 models which are predicted to have the narrowest and widest of the CD4bs apertures (30 and 36 Ã…, respectively). Overlays of these molecular models revealed a high degree of structural similarity within the V1V2 stem region, but notable structural variation within the V5 loop region (Figure 4A). Furthermore, sequence analysis of all the primary Env clones showed a relatively high degree of sequence homology within the V1V2 stem region (Figure 4B), but a relatively high degree of sequence variation within the V5 loop (Figure 4C). Together, these results suggest that, in this new panel of Envs, alteration in the width of the CD4bs cavity is likely to be due to sequence variability within the V5 region of gp120 which repositions the V5 loop.

Figure 4
figure 4

Repositioning of the V5 loop is associated with structural alterations in the CD4bs cavity. The gp120 models of CB3sc2 and Macs1br3 Envs (grey and blue ribbon representation, respectively) were superimposed, and their molecular surfaces were presented as blue or grey wire mesh (A). The consensus V1V2 stem (B) and V5 loop sequence (C) was deduced for all 81 primary Envs, and the degree of conservation at each amino acid position was calculated. The GAG linker sequence, which replaced the V1V2 loops in the crystal and model structures, is shown and highlighted as a grey box in panel (B).

Full size image

Conclusions

Using a large, independent panel of Envs, we confirmed that structural alterations in the gp120 CD4bs can be deduced using optimized three-dimensional gp120 molecular models, and that these alterations may influence fusogenicity and the ability of gp120 to interact with CD4. We further show, for the first time, that these alterations appear to increase the exposure of the CD4bs. Thus, our study provides new insights into structural mechanisms that contribute to altered interactions between gp120 and CD4. These insights contribute to a better understanding of HIV-1 entry and in addition, may inform the design of Env vaccine immunogens where enhanced exposure of the CD4bs may be desirable to elicit effective neutralizing antibody responses. Furthermore, our modeling approach may be informative for better understanding structural mechanisms contributing to HIV-1 disease progression. Here, we finally describe and characterize a new and relatively large panel of functional Envs from brain and other tissues, which will enhance the capacity of investigators to undertake NeuroAIDS research.

Abbreviations

HIV-1:

Human immunodeficiency virus type 1

SIV:

Simian immunodeficiency virus

SHIV:

Simian-human immunodeficiency virus

Env:

HIV-1 envelope glycoproteins

CD4bs:

CD4 binding site

GFP:

Green fluorescent protein

RMSD:

Room mean squared deviation

sCD4:

soluble CD4

mAb:

monoclonal antibody

BR:

Brain

CSF:

Cerebrospinal fluid

PBMC:

Peripheral blood mononuclear cells

SC:

Spinal cord

Spln:

Spleen

LN:

Lymph node

References

  1. Chan DC, Fass D, Berger JM, Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997, 89: 263-273. 10.1016/S0092-8674(00)80205-6.

    Article  CAS  PubMed  Google Scholar 

  2. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure. 2000, 8: 1329-1339. 10.1016/S0969-2126(00)00547-5.

    Article  CAS  PubMed  Google Scholar 

  3. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998, 393: 648-659. 10.1038/31405.

    Article  CAS  PubMed  Google Scholar 

  4. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984, 312: 763-767. 10.1038/312763a0.

    Article  CAS  PubMed  Google Scholar 

  5. Doms RW: Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology. 2000, 276: 229-237. 10.1006/viro.2000.0612.

    Article  CAS  PubMed  Google Scholar 

  6. Doms RW, Trono D: The plasma membrane as a combat zone in the HIV battlefield. Genes Dev. 2000, 14: 2677-2688. 10.1101/gad.833300.

    Article  CAS  PubMed  Google Scholar 

  7. Gorry PR, Ancuta P: Coreceptors and HIV-1 pathogenesis. Current HIV/AIDS Reports. 2011, 8: 45-53. 10.1007/s11904-010-0069-x.

    Article  PubMed  Google Scholar 

  8. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC: Structure of an unliganded simian immunodeficiency virus gp120 core. Nature. 2005, 433: 834-841. 10.1038/nature03327.

    Article  CAS  PubMed  Google Scholar 

  9. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, et al: Structure of a V3-containing HIV-1 gp120 core. Science. 2005, 310: 1025-1028. 10.1126/science.1118398.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, Wyatt R, Sodroski J, Doyle ML: Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci USA. 2000, 97: 9026-9031. 10.1073/pnas.97.16.9026.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998, 393: 705-711. 10.1038/31514.

    Article  CAS  PubMed  Google Scholar 

  12. Wyatt R, Sodroski J: The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science. 1998, 280: 1884-1888. 10.1126/science.280.5371.1884.

    Article  CAS  PubMed  Google Scholar 

  13. Sterjovski J, Churchill MJ, Roche M, Ellett A, Farrugia W, Wesselingh SL, Cunningham AL, Ramsland PA, Gorry PR: CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity. Virology. 2011, 410: 418-428. 10.1016/j.virol.2010.12.010.

    Article  CAS  PubMed  Google Scholar 

  14. Thomas ER, Dunfee RL, Stanton J, Bogdan D, Taylor J, Kunstman K, Bell JE, Wolinsky SM, Gabuzda D: Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology. 2007, 360: 105-119. 10.1016/j.virol.2006.09.036.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Sodroski J, Goh WC, Rosen C, Campbell K, Haseltine WA: Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature. 1986, 322: 470-474. 10.1038/322470a0.

    Article  CAS  PubMed  Google Scholar 

  16. LaBonte JA, Patel T, Hofmann W, Sodroski J: Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells. J Virol. 2000, 74: 10690-10698. 10.1128/JVI.74.22.10690-10698.2000.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Wade J, Sterjovski J, Gray L, Roche M, Chiavaroli L, Ellett A, Jakobsen MR, Cowley D, da Fonseca Pereira C, Saksena N, et al: Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection. Virology. 2010, 396: 246-255. 10.1016/j.virol.2009.10.029.

    Article  CAS  PubMed  Google Scholar 

  18. Etemad-Moghadam B, Rhone D, Steenbeke T, Sun Y, Manola J, Gelman R, Fanton JW, Racz P, Tenner-Racz K, Axthelm MK, et al: Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J Virol. 2001, 75: 5646-5655. 10.1128/JVI.75.12.5646-5655.2001.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, Lee J, Sodroski J: Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol. 2000, 74: 4433-4440. 10.1128/JVI.74.9.4433-4440.2000.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Karlsson GB, Halloran M, Schenten D, Lee J, Racz P, Tenner-Racz K, Manola J, Gelman R, Etemad-Moghadam B, Desjardins E, et al: The envelope glycoprotein ectodomains determine the efficiency of CD4+ T lymphocyte depletion in simian-human immunodeficiency virus-infected macaques. J Exp Med. 1998, 188: 1159-1171. 10.1084/jem.188.6.1159.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Liu ZQ, Muhkerjee S, Sahni M, McCormick-Davis C, Leung K, Li Z, Gattone VH, Tian C, Doms RW, Hoffman TL, et al: Derivation and biological characterization of a molecular clone of SHIV(KU-2) that causes AIDS, neurological disease, and renal disease in rhesus macaques. Virology. 1999, 260: 295-307. 10.1006/viro.1999.9812.

    Article  CAS  PubMed  Google Scholar 

  22. Si Z, Gorry P, Babcock G, Owens CM, Cayabyab M, Phan N, Sodroski J: Envelope glycoprotein determinants of increased entry in a pathogenic simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys. AIDS Res Hum Retroviruses. 2004, 20: 163-173. 10.1089/088922204773004888.

    Article  CAS  PubMed  Google Scholar 

  23. Gonzalez-Scarano F, Martin-Garcia J: The neuropathogenesis of AIDS. Nat Rev Immunol. 2005, 5: 69-81. 10.1038/nri1527.

    Article  CAS  PubMed  Google Scholar 

  24. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, Bell JE, Bannert N, Crawford K, Wang H, et al: Macrophage Tropism of Human Immunodeficiency Virus Type 1 Isolates from Brain and Lymphoid Tissues Predicts Neurotropism Independent of Coreceptor Specificity. J Virol. 2001, 75: 10073-10089. 10.1128/JVI.75.21.10073-10089.2001.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, Farzan M, Wang H, Bell JE, Kunstman K, et al: Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol. 2002, 76: 6277-6292. 10.1128/JVI.76.12.6277-6292.2002.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Cowley D, Gray LR, Wesselingh SL, Gorry PR, Churchill MJ: Genetic and functional heterogeneity of CNS-derived tat alleles from patients with HIV-associated dementia. J Neurovirol. 2011, 17: 70-81. 10.1007/s13365-010-0002-5.

    Article  CAS  PubMed  Google Scholar 

  27. Gray LR, Gabuzda D, Cowley D, Ellett A, Chiavaroli L, Wesselingh SL, Churchill MJ, Gorry PR: CD4 and MHC class 1 down-modulation activities of nef alleles from brain- and lymphoid tissue-derived primary HIV-1 isolates. J Neurovirol. 2011, 17: 82-91. 10.1007/s13365-010-0001-6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski J, Morgado M, Galvao-Castro B, von Briesen H, et al: Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol. 1996, 70: 1651-1667.

    PubMed Central  CAS  PubMed  Google Scholar 

  29. Gray L, Churchill MJ, Keane N, Sterjovski J, Ellett AM, Purcell DFJ, Poumbourios P, Kol C, Wang B, Saksena N, et al: Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoprotiens derived from two individuals homozygous for the CCR5delta32 allele. J Virol. 2006, 80: 3684-3691. 10.1128/JVI.80.7.3684-3691.2006.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Gray L, Roche M, Churchill MJ, Sterjovski J, Ellett A, Poumbourios P, Sheffief S, Wang B, Saksena N, Purcell DF, et al: Tissue-specific sequence alterations in the human immunodeficiency virus type 1 envelope favoring CCR5 usage contribute to persistence of dual-tropic virus in the brain. J Virol. 2009, 83: 5430-5441. 10.1128/JVI.02648-08.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, Taylor J, Levy R, Murphy RL, Wolinsky SM, Gabuzda D: Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol. 2003, 77: 12336-12345. 10.1128/JVI.77.22.12336-12345.2003.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Sterjovski J, Roche M, Churchill MJ, Ellett A, Farrugia W, Gray LR, Cowley D, Poumbourios P, Lee B, Wesselingh S, et al: An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology. 2010, 404: 269-278. 10.1016/j.virol.2010.05.006.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Roche M, Jakobsen MR, Sterjovski J, Ellett A, Posta F, Lee B, Jubb B, Westby M, Lewin SR, Ramsland PA, et al: HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp120-CCR5 engagement that attenuates macrophage-tropism. J Virol. 2011, 85: 4330-4342. 10.1128/JVI.00106-11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Dunfee RL, Thomas ER, Gorry PR, Wang J, Taylor J, Kunstman K, Wolinsky SM, Gabuzda D: The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci USA. 2006, 103: 15160-15165. 10.1073/pnas.0605513103.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Sterjovski J, Churchill MJ, Ellett A, Gray LR, Roche MJ, Dunfee RL, Purcell DF, Saksena N, Wang B, Sonza S, et al: Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology. 2007, 4: 89-10.1186/1742-4690-4-89.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Yang X, Tomov V, Kurteva S, Wang L, Ren X, Gorny MK, Zolla-Pazner S, Sodroski J: Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J Virol. 2004, 78: 12975-12986. 10.1128/JVI.78.23.12975-12986.2004.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Sali A, Blundell TL: Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993, 234: 779-815. 10.1006/jmbi.1993.1626.

    Article  CAS  PubMed  Google Scholar 

  38. Laskowski RA, MacArthur MW, Moss DS, Thornton JM: PROCHECK - a program to check the stereochemical quality of protein structures. Journal of Applied Crystallography. 1993, 26: 283-291. 10.1107/S0021889892009944.

    Article  CAS  Google Scholar 

  39. Gray L, Churchill MJ, Sterjovski J, Witlox K, Learmont J, Sullivan JS, Wesselingh SL, Gabuzda D, Cunningham AL, McPhee DA, Gorry PR: Phenotype and envelope gene diversity of nef-deleted HIV-1 isolated from long term survivors infected from a single source. Virology J. 2007, 4: 75-10.1186/1743-422X-4-75.

    Article  Google Scholar 

Download references

Acknowledgements and funding

We thank D. Gabuzda for providing primary HIV-1 isolates, J. Sodroski for providing pSVIII-HXB2 Env plasmid and Cf2th-CD4/CCR5 cells, J. Sodroski and B. Etemad-Gilbertson for providing Cf2-Luc cells, D. Kabat for providing JC53 cells, and H. Gottlinger for providing pSLV-Tat plasmid.

This study was supported by grants from the Australian National Health and Medical Research Council (NHMRC) to PRG and MJC (433915 & 433920). LG is the recipient of a NHMRC Peter Doherty Fellowship. PRG is the recipient of a NHMRC Level 2 Biomedical Career Development Award. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute.

Author information

Authors and Affiliations

  1. Center for Virology, Burnet Institute, Commercial Rd, Melbourne, 3004, Australia

    Lachlan Gray, Jasminka Sterjovski, Melissa J Churchill & Paul R Gorry

  2. Department of Biochemistry and Molecular Biology, Monash University, Wellington Rd, Clayton, 3800, Australia

    Lachlan Gray

  3. Center for Immunology, Burnet Institute, Commercial Rd, Melbourne, 3004, Australia

    Paul A Ramsland

  4. Department of Immunology, Monash University, Commercial Rd, Melbourne, 3004, Australia

    Paul A Ramsland

  5. Department of Surgery (Austin Health), University of Melbourne, Studley Rd, Heidelberg, 3084, Australia

    Paul A Ramsland

  6. Department of Microbiology, Monash University, Wellington Rd, Clayton, 3800, Australia

    Melissa J Churchill

  7. Department of Medicine, Monash University, Commercial Rd, Melbourne, 3004, Australia

    Paul R Gorry

  8. Department of Microbiology and Immunology, University of Melbourne, Royal Pde, Parkville, 3010, Australia

    Paul R Gorry

Authors
  1. Lachlan Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jasminka Sterjovski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul A Ramsland
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melissa J Churchill
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paul R Gorry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul R Gorry.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

LG, JS and PRG designed the experiments. LG and JS performed the experiments. JS and PAR designed the molecular models and interpreted the modeling data. MJC assisted with Env cloning and sequencing, and helped interpret the results. PRG supervised the project and helped interpret the results. LG and PRG wrote the manuscript. All authors helped edit the manuscript and have read and approved the final version.

Authors’ original submitted files for images

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Gray, L., Sterjovski, J., Ramsland, P.A. et al. Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues. Retrovirology 8, 42 (2011). https://doi.org/10.1186/1742-4690-8-42

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/1742-4690-8-42

Keywords

Retrovirology

ISSN: 1742-4690

Contact us